| Name |
Relenza 5 mg/dozi, prašak inhalata, dozirani |
| Marketing Authorisation Number |
HR-H-442926310 |
| Active Substance |
zanamivir |
| Composition |
svaka odmjerena doza praška inhalata (jedan mjehurić) sadrži 5 mg zanamivira, što odgovara isporučenoj dozi (preko nastavka za usta diskhalera) od 4,0 mg zanamivira |
| Pharmaceutical Form |
prašak inhalata, dozirani |
| Manufacturer |
Glaxo Wellcome Production, Evreux, Francuska |
| Marketing Authorisation Holder |
GlaxoSmithKline Trading Services Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Irska |
| Marketing Authorisation Date |
20.08.2021 |
| MA Period of Validity |
unlimited |
| Classification Number |
UP/I-530-09/16-02/514 |
| Registration Number |
381-12-01/70-21-37 |
| Prescription |
Medicinal product subject to medical prescription |
| Type of prescription |
neponovljivi recept
|
| Distribution |
Supply through pharmacies (community) |
| Advertising to general public |
not allowed |
| ATC Code |
J05AH01 |
| Marketing status |
nije stavljeno u promet |
| SmPC |
download |
| PL |
download |
